← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,388	+2	+0.1%	$178B
2	2 Danaher DHR $158B	2,070	-8	-0.4%	$139B
3	3 Novartis NVS $279B	1,201	+21	+2%	$14.9B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,164	-27	-2%	$66.2B
5	5 Agilent Technologies A $49.1B	939	-44	-4%	$30.9B
6	6 Illumina ILMN $41B	895	-51	-5%	$27.6B
7	7 Charles River Laboratories CRL $14.4B	611	-10	-2%	$10.7B
8	8 Revvity RVTY $17B	529	-34	-6%	$12.4B
9	9 Alnylam Pharmaceuticals ALNY $30B	476	-1	-0.2%	$22.5B
10	10 DELISTED CATALENT, INC. CTLT	441	-85	-16%	$8.72B
11	11 CRISPR Therapeutics CRSP $4.86B	417	+36	+9%	$3.07B
12	12 Sarepta Therapeutics SRPT $1.78B	405	-21	-5%	$9.38B
13	13 Bruker BRKR $8.47B	357	+39	+12%	$8.73B
14	14 Ginkgo Bioworks DNA $776M	315	+2	+0.6%	$2.25B
15	15 Azenta AZTA $1.63B	306	-36	-11%	$3.11B
16	16 Ionis Pharmaceuticals IONS $7.1B	304	-10	-3%	$5.6B
17	17 Guardant Health GH $21.9B	299	+20	+7%	$3.95B
18	18 ARK Genomic Revolution ETF ARKG $2.05B	292	-5	-2%	$666M
19	19 Intellia Therapeutics NTLA $1.6B	290	-1	-0.3%	$3.19B
20	20 Qiagen QGEN $9.41B	283	-4	-1%	$6.14B
21	21 Arrowhead Research ARWR $8.25B	273	+18	+7%	$2.57B
22	22 10x Genomics TXG $9.52B	273	+15	+6%	$4.98B
23	23 Pacific Biosciences PACB $619M	271	+12	+5%	$3.37B
24	ISEE 24 DELISTED IVERIC bio, Inc. Common Stock ISEE	255	+32	+14%	$5.33B
25	25 Ultragenyx Pharmaceutical RARE $1.47B	242	+13	+6%	$3.21B